Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 16;57(8):828.
doi: 10.3390/medicina57080828.

Erythema Multiforme and COVID-19: What Do We Know?

Luigi Bennardo  1   2 , Steven Paul Nisticò  1 , Stefano Dastoli  1 , Eugenio Provenzano  2 , Maddalena Napolitano  3 , Martina Silvestri  1 , Maria Passante  1 , Cataldo Patruno  1
Affiliations
Review

Erythema Multiforme and COVID-19: What Do We Know?

Luigi Bennardo et al. Medicina (Kaunas). .

Abstract

Background: Erythema multiforme (EM) is an acute cutaneous eruption often associated with infections and more rarely with drugs. This review aimed to evaluate the association between erythema multiforme and coronavirus disease 2019 (COVID-19). Methods: A systematic search of PubMed/MEDLINE, Scimago Scopus, and ISI/Web of Science was performed. Original articles, case series, or case reports were evaluated and selected. Results: Fourteen articles were selected, describing a total of 70 patients. EM is a cutaneous eruption rarely occurring in COVID-19 and is, in most cases, associated with a hypersensitivity reaction to the virus. In these cases, EM seems to affect patients younger than 30 years or older than 55 years. Infrequently, some drugs used in the management of COVID-19 may induce EM, especially hydroxychloroquine. The three groups of patients seem to have different clinical characteristics and courses. Conclusions: From these data, it is possible to preliminarily propose that EM or EM-like eruptions linked to COVID-19 might be divided into three types: the virus-related juvenile type (affecting patients <30-year-old), the virus-related older type (affecting patients >55 years), and the drug-induced type. The occurrence of a skin rash does not seem to be related to the severity and clinical course of COVID-19.

Keywords: COVID-19; SARS-CoV-2; erythema multiforme; hydroxychloroquine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sokumbi O., Wetter D.A. Clinical features, diagnosis, and treatment of erythema multiforme: A review for the practicing dermatologist. Int. J. Dermatol. 2012;51:889–902. doi: 10.1111/j.1365-4632.2011.05348.x. - DOI - PubMed
    1. Khan P., Mudassar M., Baloch F.A., Waqas M., Khan A. Spectrum of morpholic chamnges in erythema multiforme. J. Med. Sci. 2020;28:218–222.
    1. Dastoli S., Bennardo L., Patruno C., Nisticò S.P. Are erythema multiforme and urticaria related to a better outcome of COVID-19? Dermatol. Ther. 2020;33:e13681. doi: 10.1111/dth.13681. - DOI - PMC - PubMed
    1. Jimenez-Cauhe J., Ortega-Quijano D., Carretero-Barrio I., Suarez-Valle A., Saceda-Corralo D., Del Real C.M., Fernandez-Nieto D. Erythema multiforme-like eruption in patients with COVID-19 infection: Clinical and histological findings. Clin. Exp. Dermatol. 2020;45:892–895. doi: 10.1111/ced.14281. - DOI - PMC - PubMed
    1. García-Gil M.F., García García M., Monte Serrano J., Prieto-Torres L., Ara-Martín M. Acral purpuric lesions (erythema multiforme type) associated with thrombotic vasculopathy in a child during the COVID-19 pandemic. J. Eur. Acad. Dermatol. Venereol. 2020;34:e443–e445. doi: 10.1111/jdv.16644. - DOI - PMC - PubMed

Substances